Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (March 2024)
29 slides from Matinas Biopharma's investor presentation, Mar 28, 2024
Slide 1: Corporate Presentation April 2024
MATINAS BIOPHARMA Corporate Presentation April 2024 www.matinasbiopharma.com NYSE American: MTNB
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other sta
Slide 3: Investment Thesis: LNC Delivery Unlocks Therapeutic Value
Investment Thesis: LNC Delivery Unlocks Therapeutic Value > Intracellular delivery Lipid Nanocrystals > Oral aaministraton (LNCs) s Eee feereRtoticn - oe Pipeline Products Clinical Validation MAT2203 of LNC Capabilities and Opportunities > 2 > A Oral Amphotericin B - without nephrotoxicity Phase 3-r
Slide 4: Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform
Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform Delivery of small molecules and small oligonucleotides oe BBY Se pose © Successful oral delivery of therapeutics in infectious disease, as BO $553 ¢ inflammation, and oncology Extra-hepatic targeting Phosphatidyl- ‘ser
Slide 5: Phosphatidylserine Enables Cellular Targeting and Intracellular Delivery
Phosphatidylserine Enables Cellular Targeting and Intracellular Delivery Targeting Stressed Cells Externalize PS Normally,PS With cellular stress or injury, Is confined to PS moves from the inner the inner layer layer to the outer layer (facing cytosol) of the cell membrane ‘CELL MEMRANE PHOSPHATIDY
Slide 6: MAT2203: Oral Amphotericin B
MAT2203 Oral Amphotericin B Clinical Validation of LNC Delivery MATINAS ‘BIOPHARMA
Slide 7: The Growing Threat of Invasive Fungal Infections (IFIs)
The Growing Threat of Invasive Fungal Infections (IFls) WIRED Nature Reviews Microbiology 2022 The Bat Against the Fungal Apocalypse Ts Tos Secon in WHO fungal priority pathogens list to guide research, development and health action Deadly Fungal Infections Confound Doctors—It's Going to Get Worse”
Slide 8: MAT2203: Unlocking the Full Potential of Amphotericin B
MAT2203: Unlocking the Full Potential of Amphotericin B Innate Amphotericin B IV Amphotericin B = Unlocked Characteristics Limitations = Potential POTENT - Only available through Available systemically Y 12) © © broad-spectrum fungicidal Minimal drug-drug interactions Low propensity for resistance A
Slide 9: EnACT: Phase 2 Clinical Validation of Safety and Efficacy
EnACT: Phase 2 Clinical Validation of Safety and Efficacy EnACT Clinical Data in Cryptococcal Meningitis Validates the Use of the LNC Platform to Enable Oral Administration and Overcome Toxicity Exceeded the primary All patients completing No breakthrough endpoint threshold induction achieved Infect
Slide 10: Results of EnACT Published in Highly-Regarded Peer-Reviewed Journal
Results of EnACT Published in Highly-Regarded Peer-Reviewed Journal Clinical Infectious Diseases Ve! a] h ivma Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial David R. Boulware,“ Mucunguzi Atukunda,** Enock Kagimu,? Abdu K. Musubire,’ Andrew Akampurira,
Slide 11: MAT2203 Expanded Access Program - Targeted Treatment of IFIs Throughout the Body
MAT2203 Expanded Access Program - Targeted Treatment of IFls Throughout the Body Cocridoldomyeosis (2 Cases) ‘Mucor nidicola Meningitis Peneinsts eee) ee cat Meningitis io sapere cacoustus lesa Pulmonary aspergillosis: pai usar sla Preuncela Meningitis spel funiataftins hizopus miropons, perils tmig
Slide 12: MAT2203 Expanded Access/Compassionate Use Program
MAT2203 Expanded Access/Compassionate Use Program Demonstrated Efficacy in Treatment of Patients with Limited Treatment Options * 20 patients with no other treatment options have enrolled to receive or have completed treatment with MAT2203 — Notable Healthcare Institutions: NIH, University of Michig
Slide 13: Compassionate Use - Recovery from IV Amphotericin B Kidney Toxicity with MAT2203
Compassionate Use - Recovery from IV Amphotericin B Kidney Toxicity with MAT2203 A 38 y/o female with systemic lupus erythematosus on chronic hydroxychloroquine and prednisone presented with a progressively enlarging wound on her left foot. 07/2022: Patient admitted twice for dysgeusia, 05/2022: ‘na
Slide 14: High Unmet Medical Need in Invasive Aspergillosis with Limited Treatment Options
High Unmet Medical Need in Invasive Aspergillosis (IA) with Limited Treatment Options + lAisa serious, life-threatening fungal infection that occurs primarily in severely immunocompromised patients with hematologic malignancies and transplant recipients = ~15,000 new cases per year in the U.S. * WHO
Slide 15: MAT2203 Regulatory and Development Strategy
6 MAT2203 Regulatory and Development Strategy * Near-term development strategy refined to narrow initial target indication: treatment of invasive aspergillosis in patients with limited treatment options (azole-intolerant, azole-resistant, or not effectively managed with an azole) — Potential registr
Slide 16: FDA-Agreed Phase 3 Study Design in Invasive Aspergillosis (the ORALTO Trial)
FDA-Agreed Phase 3 Study Design in Invasive Aspergillosis (IA) (the “ORALTO” Trial) » To demonstrate that initial treatment with IV LAMB followed by step-down to oral MAT2203 is comparable to (noninferior) SoC treatment in adult patients with Invasive Aspergillosis (IA) who are unable to receive tre
Slide 17: MAT2203 Value Proposition
MAT2203 Value Proposition P ORAL LACK OF Safe, | rm oral step-down AMERGTENICNE" ADMINISTRATION NEPHROTOXICITY “= with a potent fungicidal age! Phase 2 N |! Y Lem Cryptococcal Meningitis » 2 > Treatment of Other IFis CrasieiCansew) is) * Prophylaxis Near-Term Development Strategy: Focused strategy o
Slide 18: LNCs Beyond Infection
LNCs Beyond Infection Efficient and Safe Delivery of Small Oligonucleotides and Chemotherapeutics in Inflammation and Oncology MATINAS ‘BIOPHARMA
Slide 19: Unlocking the Full Potential of the LNC Platform
Unlocking the Full Potential of the LNC Platform Proven Delivery of Cargo Oral Formulations » MAT2203 of Anti-Infectives » Remdesivir Oral Delivery of Small * siRNA Oligonucleotides » ASO Oral Formulations of po cetaxel Chemotherapeutics Potential Therapeutic Applications INFECTION * Anti-infectives
Slide 20: LNCs are Avidly Taken up by Innate Immune Cells - Multiple Opportunities in Inflammation
LNCs are Avidly Taken up by Innate Immune Cells - Mu/tiple Opportunities in Inflammation Percent of cells with uptake 100 80 60 40 20 Ex-vivo LNC Uptake in @ mutant hemetopoete 20 ug/ml LNe soos Human Whole Blood 512 ng/mL Cy5-labeled siRNA cargo. } 99.9 975 _ @ ® onsen wrooqmet 816 ¥ + v + t + 708
Slide 21: Effect of Oral LNC IL-17A RNAi in a Murine Imiquimod Psoriasis Model
Effect of Oral LNC IL-17A RNAi in a Murine Imiquimod (IMQ) Psoriasis Model 5 Groups bay? Naive e | *-p<0.001 (ay47) g 4g IMQ only 3 ge LNCA 2 2 panei LNc2 | 2°1ue/mouse daily oral gavage) H al é H . (n=50) ILA7A murine Ab _1me/kgi.p. god a a 2.0 5 = Change in IL47A Tissue mRNA at Day 7 Ome Ne wen wo
Slide 22: Effect of Oral LNC-TNFa RNAi in a Murine DSS Acute Colitis Model
Disease Activity Index Effect of Oral LNC-TNFa RNAi in a Murine DSS Acute Colitis Model ag Female C57BL/6 mice (n=55) 6 + 54 at = - 3 2 4 0 6 Groups Change in TNFa Tissue mRNA at Day 14 Untreated control DSS alone DSS + oral LNC 4. DSS + oral LNC 2 DSS + oral Scrambled LNCs DSS + anti-TNFa Ab 0.167
Slide 23: LNCs Target PS on Tumor Cells - Multiple Opportunities in Oncology
LNCs Target PS on Tumor Cells - Mu/tiple Opportunities in Oncology Healthy Cell Tumor Cell ‘© Phosphatidylserine (PS) PS is confined to the interior leaflet of the cellular plasma membrane PS is exposed on the surface of tumor cells LNCs nottaken up by normal cells LNCs avidly taken up by cells expr
Slide 24: In vivo Therapeutic Efficacy of Oral Docetaxel LNCs in a Murine Syngeneic Melanoma Model
/n vivoTherapeutic Efficacy of Oral Docetaxel LNCs in a Murine Syngeneic Melanoma Model 000 Female CS7BL/mic@ ant (n= 40) cells Untreated yd Day 0 Day 5 Day10 Day 14 V Docetaxel High Dose LNC- docetaxel Low Dose LNC- docetaxel g 8 ji +eme Untreated conto (vith tumor) Docetaxel 0.15 mg/mouseiv on day
Slide 25: Oral LNC Docetaxel Markedly Reduces Toxicity
Oral LNC Docetaxel Markedly Reduces Toxicity Healthy C57BL/6 mice (n = 24) 4, Study Ena - Day 22 . a eee Ora saline (conto) __ Lemtoentn ete Dacetarel 6me/mouse va weekxd ee Oral LNC-docetaxe! 0.75 mg/mouse daily trough day 22 & * oy 2: Sen KEY TAKEAWAYS 8 Ae Ne dovetare! * Through Day 22, the total
Slide 26: Recent Key Advances Highlight Broader Applicability of LNC Platform Capabilities
Recent Key Advances Highlight Broader Applicability of LNC Platform Capabilities Oncology Inflammation > Successful in vivo oral delivery of LNC-docetaxel in a » Successful in vivo oral LNC delivery of 2 different RNAi melanoma tumor model oligonucleotides targeting inflammatory cytokines + Reductio
Slide 27: Expanding LNC Intellectual Property Portfolio
Expanding LNC Intellectual Property Portfolio Increasing Patent Portfolio to Increase Protection and Exclusivity MAT2203 potentially entitled Owned and Licensed Recent patent to 12+ years of marketing Global Platform IP with applications based on exclusivity potential protection formulation work wit
Slide 28: Experienced Leadership Team
Experienced Leadership Team EXECUTIVE TEAM Jerome D. Jabbour, J.D. Chief Executive Officer Semen James Ferguson, M.D. Chief Medical Officer amon Ecce astazenecd > Thomas Hoover, MBA Chief Business Officer *Ssunovion Keith Kucinski, CPA, MBA Chief Financial Officer PAR barr ‘Theresa Matkovits, Ph.D.
Slide 29: Investment Thesis: Financial Summary and Near-Term Milestones
Investment Thesis Financial Summary Runway through Q3 2024 on ve) $13.8M" in Cash, 83 Cash Equivalents and Marketable Securities Ves erosayay2a Non-Dilutive - Financing Options Near-Term Milestones - Setup for Strong Start to 2024 v M Q1 - Successful Agreement with FDA for a Single Phase 3 Registrat
Matinas BioPharma Holdings — Investor Presentation (March 2024) on 6ix